Navigation Links
PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
Date:6/3/2009

BOSTON, June 3 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address important industry issues at the Drug Information Association (DIA) 45th Annual Meeting, being held from June 21 - 25, 2009 in San Diego, California. A number of PAREXEL's thought leaders will present on topics ranging from global development strategies, clinical logistics in emerging regions, clinical trial metrics, and drivers of investigator performance to conducting multinational trials, optimizing adaptive trial designs, preparing pharmacovigilance documents, and securing venture funding for drug development plans. PAREXEL experts will also discuss best practices for creating immunogenicity strategies, developing safe and effective biological medicines, and addressing regulatory challenges related to second generation therapeutic proteins.

PAREXEL International--Booth #1701

A complimentary white paper, entitled "Best Practices: Non Clinical Trial Safety," will be provided at PAREXEL's Booth #1701. A global team of PAREXEL experts will be available for on-site exclusive executive briefings and to discuss the Company's model for achieving optimal efficiency and effectiveness in clinical development. These experts will also address partnering best practices, including strategic guidance and creative solutions to help biopharmaceutical companies meet milestones and overcome key challenges. Other capabilities that will be presented by PAREXEL to support the successful development and commercialization of biopharmaceutical products include global market access, regulatory consulting, Phase I - IV programs, advanced technology, reimbursement, safety/pharmacovigilance, and medical communications.

Perceptive Informatics--Booth #1707

Perc
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... MONTREUX, Switzerland, Feb. 4 Patients with frequently,relapsing ... time to an,initial relapse when risperidone long-acting injection ... new study. The study compared,patients who received RLAI ... combined with placebo., The study was presented ...
... CARLSBAD, Calif., Feb. 4 Ardea Biosciences,Inc. (Nasdaq: ... virus (HIV) Scientific Advisory Board (SAB) with the,appointment of ... SAB will,provide independent scientific advice and counsel to the ... to treat HIV., "Establishing a strong scientific advisory ...
... MINNEAPOLIS, Feb. 4 Uroplasty, Inc. (Amex:,UPI) announced ... the third,quarter of fiscal 2008 ended December 31, ... 2008. The Company will host a conference call ... at 10:00 a.m. Central,Time. David Kaysen, President and ...
Cached Biology Technology:Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 3Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 4Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 5Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 2Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 3Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 4
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... new study seeks to determine how one parasitic species can ... The human body louse ( Pediculus humanus ) can transmit ... (also Pediculus humanus ) does not. A report ... Molecular Biology . "Body louse-transmitted diseases include trench fever, ...
... authors describe how in laboratory tests, they compared the ... stress by several antioxidants, some of which are found ... sunburn, UVA radiation penetrates deeper, damaging our DNA by ... skin its elastic quality. The Newcastle team found ...
... New research co-written by University of Montana scientists finds ... 31 large carnivore species. The analysis, published Jan. 9 in ... species including tiger, lion, dingo and puma are ... and John J. Craighead Chair and Professor of Wildlife Conservation ...
Cached Biology News:1 species, 2 outcomes: Team seeks source of body louse pathology 2Fresh faced: Looking younger for longer 2Fresh faced: Looking younger for longer 3Study shows large carnivore numbers and range declining worldwide 2
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Acetylcholinesterase from human and monkey....
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
... systems. , Integrated Instrument Control , ... EZChrom Elite can be configured with a ... provides a completely integrated system to control instrument's operation, collect andstore ... ...
Biology Products: